Floatz logo

Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)-

Salivary Gland Carcinoma

VM Oncology, LLCSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Salivary Gland Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
VM Oncology, LLC
Phase 2B
Anti-Her2 Antibody-Drug Conjugate A166
Klus Pharma Inc.
Phase 1/2CCC
Lenalidomide
National Cancer Institute (NCI)
Phase 1CC
Sargramostim
National Cancer Institute (NCI)
Phase 1CC
Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific
Xencor, Inc.
Phase 1CC

View all 13 →

Same molecule, other indications

Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- is also rated in:

head and neck carcinomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
refractory malignant neoplasmActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
salivary gland cancerActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →